[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,43,76,100,126,175,209,235,263],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100644474","triage-radiology-imaging-assessment-for-greater-effectiveness-100644474",false,"NCT07671664","Triage Radiology Imaging Assessment for Greater Effectiveness","Triage Radiology Imaging Assessment for Greater Effectiveness (TRIAGE): a Cluster-Randomised Crossover Trial Evaluating the Reporting Turn-Around-Time of Brain Magnetic Resonance Images Using an AI-enabled Abnormality Detector for Prioritisation","TRIAGE","Inclusion Criteria:\n\nFor main trial\n\n* Adult patient (≥ 18 years of age) at the time of MRI.\n* Brain MRI scan performed at a participating NHS site during the defined study period (intervention or control arm).\n* Brain MRI scan series will automatically be included if they contain the required scan sequences and are of the required resolution.\n\nFor O3 subgroup ● Radiologists, radiographers, and referring clinicians involved with the use of the MIDI tool at sites who consent to completing the staff survey\n\nFor O7 subgroup\n\n* Adult patient (≥ 18 years of age) at the time of MRI.\n* Brain MRI scan performed at a participating NHS site during the defined study period (intervention or control arm).\n* Brain MRI scan series will automatically be included if they contain the required scan sequences and are of the required resolution.\n* Patient with suspected de novo stroke\u002FTIA in TIA\u002FStroke pathway.\n* Patient with suspected de novo stroke\u002FTIA in Acute Neurology pathway.\n* Patient with suspected de novo stroke\u002FTIA identified via SSNAP review.\n\nFor O8 subgroup\n\n* Adult patient (≥ 18 years of age) at the time of MRI.\n* Brain MRI scan performed at a participating NHS site during the defined study period (intervention or control arm).\n* Brain MRI scan series will automatically be included if they contain the required scan sequences and are of the required resolution.\n* Patient with stage III\u002FIV malignant melanoma undergoing regular surveillance MRI brain scans presenting with de novo brain metastases.\n* Patient with lung cancer undergoing pre-radical treatment staging MRI brain scans presenting with de novo brain metastases.\n* Patients with de novo symptomatic brain metastases secondary to melanoma and\u002For lung cancer and\u002For breast cancer detected on MRI brain scans from all patient pathways.\n\nAdditionally for those completing EORTC questionnaires:\n\n● Able to give consent and likely to be able to complete EORTC questionnaires.\n\nExclusion Criteria:\n\nFor main trial\n\n* Patient is under 18 years of age at the time of MRI.\n* Brain MRI scan not performed at a participating NHS site or outside the defined study period.\n* Data will be excluded for those patients who have opted out of the use of their data for research under the National Data Opt-Out.\n* Brain MRI scan series will automatically be excluded if they do not contain the required scan sequences and\u002For the required resolution.\n\nFor O3 subgroup ● Radiologists, radiographers, and referring clinicians involved with the use of the MIDI tool at sites who do not consent to completing the staff survey\n\nFor O7 subgroup\n\n* Patient is under 18 years of age at the time of MRI.\n* Brain MRI scan not performed at a participating NHS site or outside the defined study period.\n* Data will be excluded for those patients who have opted out of the use of their data for research under the National Data Opt-Out.\n* Brain MRI scan series will automatically be excluded if they do not contain the required scan sequences and\u002For the required resolution.\n* Patient without suspected de novo stroke\u002FTIA or not on TIA\u002FStroke pathway.\n* Patient without suspected de novo stroke\u002FTIA or not on Acute Neurology pathway.\n\nFor O8 subgroup\n\n* Patient is under 18 years of age at the time of MRI.\n* Brain MRI scan not performed at a participating NHS site or outside the defined study period.\n* Data will be excluded for those patients who have opted out of the use of their data for research under the National Data Opt-Out.\n* Brain MRI scan series will automatically be excluded if they do not contain the required scan sequences and\u002For the required resolution.\n* Patient without stage III\u002FIV malignant melanoma, or not undergoing regular surveillance MRI brain scans, or not presenting with de novo brain metastases.\n* Patient without lung cancer undergoing pre-radical treatment staging MRI brain scans, or not presenting with de novo brain metastases.\n* Patients without de novo symptomatic brain metastases secondary to melanoma and\u002For lung cancer and\u002For breast cancer detected on MRI brain scans.\n\nAdditionally for those completing EORTC questionnaires:\n\n● Unable to give consent and unlikely to be able to complete EORTC questionnaires.","ALL","18 Years",{"count":20,"type":21},100800,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of the trial is to understand whether a computerised tool designed to quickly spot problems in brain scans (MIDI) can help doctors diagnose cases faster. This will help patients by getting them the treatment they need sooner. How useful doctors find the tool will also be measured, and whether it is cost-saving for the National Health Service (NHS).",[27],"Brain",[15,29,30],"MIDI","AI Brain MRI","NOT_YET_RECRUITING","2026-06-25",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":21},"2027-03",{"date":39,"type":21},"2030-03",{"name":41,"class":42},"King's College London","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100628757","a-first-in-human-study-of-the-cipher-system-during-brain-surgery-for-newly-diagnosed-glioma-100628757","NCT07465796","A First-in-Human Study of the CIPHER System During Brain Surgery for Newly Diagnosed Glioma","CIPHER","Inclusion Criteria:\n\n* Newly diagnosed supratentorial glioma requiring resection\n* Glioma mass reaches or close to cortical surface\n* Adults aged 18-75\n* Planned for open craniotomy under Total Intravenous Anesthesia (TIVA)\n* Patient able to provide informed consent\n* Performance status: Eastern Cooperative Oncology Group (ECOG) scale 0-2\n\nExclusion Criteria:\n\n* Prior craniotomy at the same anatomical location\n* Plan for awake craniotomy\n* Any history of seizures prior to craniotomy\n* Any history of coagulopathy or coagulation disorders\n* Pregnant status during craniotomy","75 Years",{"count":52,"type":21},10,[24],"The goal of this clinical trial is to collect data on the use of the CIPHER System when used by a surgeon during brain tumor removal. The main questions it aims to answer are:\n\n* To evaluate the safety of the CIPHER System when used during brain tumor surgery (Primary)\n* To evaluate the function of the electrodes under recording and stimulating conditions during surgery (Secondary) Participants will undergo standard-of-care surgery to remove their tumor. Just before the tumor is removed, the CIPHER System will be tested on the main tumor and the surrounding margin areas. Participants will be monitored during standard hospital visits occurring during the recovery period after surgery as well as two- and six-weeks after surgery.",[56,57,58,27],"Glioma","Tumor","Electrocorticography",[60,61,62,63],"Intraoperative Neurophysiology","Cortical Mapping","Cortical Stimulation","Brain-Computer Interface (BCI)","RECRUITING","2026-06-01",{"date":67,"type":35},"2026-06-03",{"date":69,"type":35},"2026-05-22",{"date":71,"type":21},"2026-09",{"name":73,"class":74},"Coherence Neuro Australia Pty Limited","INDUSTRY",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":75},"100432864","a-first-ever-research-collaboration-to-characterize-mri-measured-neural-flexibility-development-in-chinese-toddlers-100432864","NCT04916652","A First-ever Research Collaboration to Characterize MRI Measured Neural Flexibility Development in Chinese Toddlers","Inclusion Criteria:\n\n1. Written informed consent has been obtained from the parent\u002Flegally acceptable representative.\n2. Full-term birth (≥ 37 weeks and ≥ 2.5kg)\n3. Typically developing Children aged between 32-34 months (2 years 8 months to 2 years10 month of age) at enrolment\n4. Neurotypical development as assessed by interview\n5. No major risk factors for learning, neurologic, or psychiatric disorder as assessed by interview \\[defined as a diagnosed learning neurologic or psychiatric disorder in a first degree relative (e.g. parents, siblings)\\].\n6. Dietary requirement detailed below:\n\nS-26 GOLD or ULTIMA GUM--fed group:\n\nI. Daily consumption of S-26 GOLD or ULTIMA GUM for the last 60 days (2 months) II. Desire of the parent to continue feeding GUM during the course of the study\n\nCow's milk-fed group:\n\nI. Daily consumption of cow's milk or for the last 60 days (2 months) II. Desire of the parent to continue feeding cow's milk during the course of the study\n\nExclusion Criteria:\n\n1. Delayed birth ( \\> 41 weeks gestation) as reported in medical record\n2. Birth Weight \\\u003C 2500 g or small for gestational age (birth weight below the 10th percentile) or large for gestational age (birth weight above the 90th percentile) as reported in medical record\n3. History of neurological (e.g., head injury, epilepsy), psychiatric or developmental disorder in the toddler as assessed by interview\n4. History of diagnosed neurological (e.g., head injury, epilepsy), psychiatric or developmental disorder in parents or siblings, as assessed by interview\n5. In utero exposure to alcohol abuse or illicit substances as defined as diagnosis of current substance use disorder in the biological mother and guidelines set by the American College of Obstetricians and Gynecologists and the Royal College of Physicians\n6. Multiple birth as reported in medical record\n7. Complicated pregnancy (e.g., preeclampsia, gestational diabetes) as assessed by medical interview\u002F medical record\n8. Abnormal screening laboratory values and studies considered to be clinically significant in the opinion of the Investigator (e.g., metabolic disease screening, neonatal bilirubin)",true,"32 Months","34 Months",{"count":86,"type":21},60,"OBSERVATIONAL","The overall objective is to characterize the developmental characteristics of MRI measured neural flexibility, as an index of cognitive flexibility, in Chinese toddlers (32 to 42 months old).",[90,27],"Growth & Development","2025-11-26",{"date":93,"type":35},"2025-12-03",{"date":95,"type":35},"2024-04-06",{"date":97,"type":21},"2027-02",{"name":99,"class":74},"Société des Produits Nestlé (SPN)",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":82,"sex":17,"minAge":107,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":75},"100608955","cognitive-vitality-pilot-study-100608955","NCT07208279","Cognitive Vitality Pilot Study","Effects of Dietary Supplement Intervention on Cognitive Function and Psychological Well-Being","Inclusion Criteria:\n\n* Adults aged 55 years and older\n* Live independently,\n* Self-report as healthy\n* Adequate vision\n* Fluent in English\n* No history of mild cognitive impairment\n* Currently not taking dietary supplements with the same active ingredients in Axolt or naturally flavored water\n* A Montreal Cognitive Assessment \\[12\\] (MOCA) score ≥ 24\n* Able to provide written informed consent, and medical clearance to participate.\n\nExclusion Criteria:\n\n* Previous participation in a cognitive dietary supplement study in the last 12 months\n* A score of \\\u003C 24 on the Montreal Cognitive Assessment (MoCA) as a potential risk for obtaining informed consent\n* History of seizures\n* Epilepsy\n* Parkinson's disease\n* History of severe head trauma\n* Uncontrolled hypertension\n* On psychoactive medications\n* Substance abuse\n* Unwilling or unable to discontinue current dietary supplements with similar ingredients\n* Planned surgery during the study period\n* Medications known to interact with active ingredients with Axolt\n* Minors and prisoners will be excluded.","55 Years",{"count":109,"type":21},16,[24],"This study's purpose is to evaluate the effects of a dietary supplement on cognitive function and psychological well-being in community-dwelling older adults aged 55+. The study involves taking a commercially available dietary supplement daily for 45 days. A 45-minute assessment will be conducted at the beginning and again at the end of the study.",[113,114,115,116,27],"Aging","Healthy Aging","Cognition","Memory","2025-10-27",{"date":119,"type":35},"2025-10-28",{"date":121,"type":35},"2025-09-01",{"date":123,"type":21},"2026-08-11",{"name":125,"class":42},"Arizona State University",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":82,"sex":17,"minAge":107,"maxAge":134,"enrollmentInfo":135,"targetDuration":137,"studyType":87,"phases":4,"briefSummary":138,"conditions":139,"keywords":152,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":75},"100464026","biobank-and-brain-health-in-bordeaux-100464026","NCT05322343","Biobank and Brain Health in Bordeaux.","Biobank and Brain Health in Bordeaux. A Population-based Cohort to Study the Biology of Brain and Cognitive Aging in Young Seniors","B-cube","Inclusion Criteria:\n\nFor the main study:\n\n1. live in Bordeaux metropolitan area,\n2. be between 55 and 80 years old (included),\n3. selected in terms of socioeconomic level, according to a sampling strategy by age groups and income categories representative of the general population between 55 and 80 years of age\n4. be affiliated with the social security system,\n5. agree to take a blood sample for the biobank.\n\nFor the MRI sub-study: be between 55 and 75 years old (included). Inclusion criteria for the immune response substudy: be 70 years of age or older or participate in the MRI study; agree to take a supplemental blood sample for this substudy.\n\nExclusion Criteria:\n\nFor the main study: persons under guardianship (or more generally under protection), unable to give consent to participate.\n\nFor the MRI sub-study: have a contraindication to MRI examination (pacemaker, a valve prosthesis or any other internal electrical\u002Fmagnetic device; history of neurosurgery or aneurysm; claustrophobia; presence of metal fragments in the eyes, brain or spinal cord).","80 Years",{"count":136,"type":21},2050,"12 Months","B cube is a new generation cohort to study the determinants and natural history of brain aging, using molecular epidemiology, in a representative sample (N=2000) of the general population from the age of 55 (the approximate age of onset of the first cognitive disorders and a target population particularly receptive to prevention messages). Special interest will be given to nutrition, a promising environmental exposure for prevention.",[27,113,140,141,142,143,144,115,145,146,147,148,149,150,151],"Cognitive Aging","Immunosenescence","Mental Processes","Mental Disorders","Neurocognitive Disorders","Brain Diseases","Dementia","Alzheimer Disease","Mental Health","Behavioral Symptoms","Depression","Anxiety",[153,154,155,156,157,158,159,160,161,162,163,164,165],"Epidemiologic Methods","Risk factors","Public Health","Environmental Exposure","Exposome","Dietary Exposure","Diet","Food and Nutrition","Nutritional Status","Metabolomics","Systems biology","Environmental Biomarkers","Inflammation Mediators","2025-08-08",{"date":168,"type":35},"2025-08-11",{"date":170,"type":35},"2022-03-22",{"date":172,"type":21},"2030-03-22",{"name":174,"class":42},"University Hospital, Bordeaux",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":182,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":185,"conditions":186,"keywords":192,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":75},"100467852","vanderbilt-memory-and-aging-project-100467852","NCT05372159","Vanderbilt Memory and Aging Project","VMAP","Inclusion Criteria:\n\n* Participants recruited will include 1,000 adults age 50 and older.\n* After the eligibility visit, a small portion of participants (\\~150) enrolling must meet diagnostic criteria for mild cognitive impairment according to a clinician diagnosis and\u002For medical records (i.e., participants must have mild memory or cognitive problems, but they must be free of any functional problems and not have Alzheimer's disease or another form of dementia). The remaining \\~850 participants will be cognitively unimpaired adults age 50 and older.\n* Because the neuropsychological tests used to measure cognitive performance are validated on English-speaking populations, we require that English be the primary language of all participants.\n\nExclusion Criteria:\n\n* No available reliable study partner\n* History of major psychiatric illness (e.g., schizophrenia, bipolar), neurological illness (e.g., stroke, epilepsy, multiple sclerosis, Parkinson's disease, dementia), or head injury with significant loss of consciousness. These exclusion criteria have been applied because they affect brain structure and function.\n* Diagnosis of congestive heart failure\n* Diagnosis of atrial fibrillation or other heart arrhythmia\n* Diagnosis of Chronic obstructive pulmonary disease\n* Diagnosis of cancer (current)\n* History of serious alcohol or drug abuse (past or current)\n* Participants unable to undergo MRI will be excluded. Reasons may include: a. Subjects who have any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.). b. Subjects who have any type of ferromagnetic bioimplant that could potentially be displaced. c. Subjects who have cerebral aneurysm clips. d. Subjects who may have shrapnel imbedded in their bodies (e.g., from war wounds), metal workers and machinists (e.g., potential for metallic fragments in or near the eyes). e. Subjects who are pregnant. Given that the minimum age of recruitment for the current study is 50 years of age, it is unlikely that prospective participants will be excluded because of pregnancy. f. Subjects who have excessive amounts of metal dental work based on records released by their dentist.","60 Years",{"count":184,"type":21},1000,"This study will use an observational cohort to cross-sectionally and longitudinally relate vascular health to clinical, imaging, and biological markers of early Alzheimer's disease and cerebrovascular disease among aging adults. Adjusting for relevant clinical covariates, we will test the hypothesis that vascular health is associated with clinical, brain magnetic resonance imaging (MRI), neuropsychological, and cerebrospinal fluid markers of early cerebrovascular and Alzheimer's disease changes (i.e., prior to the onset of significant cognitive decline or dementia). Secondarily, we will examine medical and genetic factors that might mediate associations between vascular health and brain aging, such as inflammatory processes, insulin resistance, and genetic factors (e.g., APOE, a susceptibility risk factor for dementia). Findings will advance knowledge regarding the role that vascular health plays in brain aging.",[147,113,187,188,27,189,190,191],"Aged, 80 and Over","Biomarkers","Case-Control Studies","Cognitive Dysfunction","Neuropsychological Tests",[193,194,195,196,197,198,199],"Alzheimer's disease","biomarkers","brain MRI","cardiac MRI","mild cognitive impairment","vascular risk factors","longitudinal studies","2025-08-01",{"date":202,"type":35},"2025-08-06",{"date":204,"type":35},"2012-09-17",{"date":206,"type":21},"2026-12-31",{"name":208,"class":42},"Vanderbilt University Medical Center",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":75},"100504038","the-stereo-dbs-study-7-tesla-mri-brain-network-analysis-for-deep-brain-stimulation-100504038","NCT05843084","The STEREO-DBS Study: 7-Tesla MRI Brain Network Analysis for Deep Brain Stimulation","STEREO-DBS","1.2 Inclusion criteria\n\nIn order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n* Age \\> 18 years;\n* Idiopathic PD who underwent STN DBS\n\n1.3 Exclusion criteria\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Legally incompetent adults;\n* No written informed consent.",{"count":217,"type":21},500,"Rationale: Deep brain stimulation (DBS) of the nucleus subthalamicus (STN) is an effective surgical treatment for the patients with advanced Parkinson's disease, despite optimal pharmacological treatment. However, individual improvement after DBS remains variable and 50% of patients show insufficient benefit. To date, DBS-electrode placement and settings in the highly connected STN are based on 1,5-Tesla or 3-Tesla MR-images. These low resolution and solely structural modalities are unable to visualize the multiple brain networks to this small nucleus and prevent electrode activation directed at its cortical projections. By using structural 7-Tesla MRI (7T MRI) connectivity to visualize (malfunctioning) brain networks, DBS-electrode placement and activation can be individualized.\n\nObjective: Primary objective of the study is to determine whether visualisation of cortical projections originating in the STN and the position of the DBS electrode relative to these projections using 7T MRI improves motor symptoms as measured by the disease-specific Unified Parkinson's Disease Rating Scale (UPDRS-III).\n\nSecondary outcomes are: disease related daily functioning, adverse effects, operation time, quality of life, patient satisfaction with treatment outcome and patient evaluation of treatment burden.\n\nStudy design: The study will be a single center prospective observational study.\n\nStudy population: Enrollment will be ongoing from April 2022. Intervention (if applicable): No intervention will be applied. Application of 7T MRI for DBS is standard care and outcome scores used will be readily accessible from the already existing advanced electronic DBS database.\n\nMain study parameters\u002Fendpoints: The primary outcome measure is the change in motor symptoms as measured by the disease-specific Unified Parkinson's Disease Rating Scale (UPDRS-III). This is measured after 6 months of DBS as part of standard care. The secondary outcome measures are the Amsterdam Linear Disability Score for functional health status, Parkinson's Disease Questionnaire 39, Starkstein apathy scale, patient satisfaction with the treatment, patient evaluation of treatment burden, operating time, hospitalization time, change of tremor medication, side effects and complications.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: The proposed observational research project involves treatment options that are standard care in daily practice. The therapies will not be combined with other research products. Participation in this study constitutes negligible risk according to NFU criteria for human research.",[220,221,27,222,223,224,225],"Parkinson Disease","Diffusion Magnetic Resonance Imaging","Subthalamic Nucleus","Deep Brain Stimulation","Human","Treatment Outcome","2025-07-22",{"date":228,"type":35},"2025-07-25",{"date":230,"type":35},"2022-04-11",{"date":232,"type":21},"2033-04-11",{"name":234,"class":42},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":262},"100482662","a-ketogenic-diet-as-a-complementary-treatment-on-patients-with-high-grade-gliomas-and-brain-metastases-100482662","NCT05564949","A Ketogenic Diet as a Complementary Treatment on Patients With High-grade Gliomas and Brain Metastases","A \"Classic\" Ketogenic Diet as a Complementary Therapeutic Management on Patients With High-grade Gliomas and Brain Metastases.","Inclusion Criteria:\n\n* Age 18-80\n* Karnofsky Performance Score of 50 or more.\n* Newly diagnosed, histologically confirmed glioblastoma grade 4, or secondary metastases or progression after surgical resection, radiation and chemotherapy.\n* Normal function of liver and kidneys\n* Ability to sign informed consent form\n\nExclusion Criteria:\n\n* Diabetes mellitus\n* Life expectancy \\>3 months\n* Inability to adhere to diet\n* Inability to give informed consent form\n* Cholecystectomy last 1 year (before the study entry)\n* Diagnosis of genetic disorder of fat metabolism",{"count":243,"type":21},15,[24],"The survival interval of patients with gliomas ranges between 12 to 15 months. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect. Ketosis can be an effective therapy to extend the survival of patients with gliomas.",[27,247],"Cancer",[249,250,251,252],"ketogenic","diet","gliomas","metastases","2025-05-27",{"date":255,"type":35},"2025-05-31",{"date":257,"type":35},"2022-09-20",{"date":259,"type":21},"2026-02-28",{"name":261,"class":42},"Attikon Hospital",2,{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":281,"leadSponsor":283,"locationsCount":75},"100585051","comparing-brain-cortical-activity-in-real-and-immersive-virtual-reality-manual-dexterity-tasks-100585051","NCT06897332","Comparing Brain Cortical Activity in Real and Immersive Virtual Reality Manual Dexterity Tasks","Inclusion Criteria:\n\n* Age over 18 years old\n* Normal-to-corrected vision\n* Ability to understand simple instructions\n\nExclusion Criteria:\n\n* History of seizure\n* Recent participation (within the last three months) in a study involving a manual dexterity task in immersive virtual reality\n* Neurologic or orthopaedic pathology potentially affecting upper extremity movement",{"count":270,"type":21},12,"With advances in technology, virtual reality (VR) is increasingly used in various fields, including rehabilitation, motor learning, and neuroscience. Its ability to provide controlled, immersive, and interactive environments makes it a valuable tool for training and assessment. However, despite its growing adoption, limited evidence exists on how cortical activation in VR compares to real-world conditions. Moreover, brain cortical activity during motor tasks, such as manual dexterity tasks, remains underexplored.\n\nThis study aims to compare brain cortical activity in real and immersive virtual reality settings during a manual dexterity task. Secondary objectives include:\n\n* Examining the relationship between brain cortical activity and kinematics in both conditions.\n* Comparing brain cortical activity between hand-tracking and controller-based interactions.",[27,273,274,275,276],"Virtual Reality","EEG","fNIRS","Manual Dexterity","2025-03-20",{"date":279,"type":35},"2025-03-26",{"date":277,"type":21},{"date":282,"type":21},"2025-06-30",{"name":284,"class":42},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain"]